Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond [0.03%]
中重度特应性皮炎的单克隆抗体治疗：III期及以后研究一览
Eden David,Kelly Hawkins,Neda Shokrian et al.
Eden David et al.
Introduction: The understanding of atopic dermatitis (AD) pathogenesis has rapidly expanded in recent years, catalyzing the development of new targeted monoclonal antibody treatments for AD. ...
Management of proctitis in ulcerative colitis and the place of biological therapies [0.03%]
溃疡性结肠炎直肠炎的处理及生物制剂的作用
Diletta De Deo,Arianna Dal Buono,Roberto Gabbiadini et al.
Diletta De Deo et al.
Introduction: Approximately 20-30% of the patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of...
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer [0.03%]
Nadofaragene Firadenovec-vncg治疗高危卡介苗耐药非肌层浸润性膀胱癌疗效的评估
Zine-Eddine Khene,Yair Lotan
Zine-Eddine Khene
Introduction: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) represent a significant therapeutic challenge in the treatment of bladder cancer. Nadofaragene firadenovec, represents a breakthrough in this area,...
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma [0.03%]
晚期食管鳞癌二线抗肿瘤抗体治疗进展
Nozomu Ogura,Shun Yamamoto,Ken Kato
Nozomu Ogura
Introduction: The prognosis of advanced esophageal squamous cell carcinoma (ESCC) is poor. Although cytotoxic drugs have been widely used in advanced ESCC, several antibody agents have recently been reported to be effecti...
Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market [0.03%]
西班牙的生物类似药概览：市场动态、政策、循证见解及可持续发展的途径
Isabel Río-Álvarez,Encarnación Cruz-Martos
Isabel Río-Álvarez
Introduction: After 17 years on the market, biosimilar medicines have contributed significantly to the sustainability of healthcare in Spain, providing cost-effective treatment options and savings of more than €1 billion...
Understanding patient variability to biologic treatments in inflammatory bowel disease [0.03%]
炎症性肠病生物制剂治疗的患者差异研究进展
Ahmad Z Al Meslamani
Ahmad Z Al Meslamani
Peter E Penson,Alice P McCloskey
Peter E Penson
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network [0.03%]
生物制剂在银屑病和银屑病关节炎患者中的转换模式：来自VALORE数据库网络的见解
Andrea Spini,Giorgia Pellegrini,Ylenia Ingrasciotta et al.
Andrea Spini et al.
Background: Switch patterns among different biologics and from originators to biosimilars (and vice versa) can be complex in patients with psoriasis (PsO) and psoriatic arthritis (PsA). ...
Tsz Ching Mok,Chi Chiu Mok
Tsz Ching Mok
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease that affects both the articular and extra-articular structures, leading to significant joint damage, disability and excess mortality. The...
Hampus Andersson,Barnabas Nyesiga,Tova Hermodsson et al.
Hampus Andersson et al.
Introduction: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity ...